Skye Bioscience, Inc.
Skye Bioscience is a biotechnology company focused on developing next-generation drugs to treat obesity and other metabolic diseases. They are advancing first-in-class molecules that modulate G-protein coupled receptors, with a particular emphasis on peripheral CB1 inhibition as a differentiated mechanism for weight loss and metabolic health. The company aims to address unmet needs in obesity treatment by offering therapies that promote sustainable weight loss, improve metabolic conditions, and have better tolerability.
Industries
Nr. of Employees
small (1-50)
Skye Bioscience, Inc.
11250 El Camino Real, Suite 100, San Diego, CA 92130
Products
Investigational peripheral CB1-inhibiting monoclonal antibody (investigational obesity candidate)
A peripherally restricted monoclonal antibody that negatively modulates the CB1 receptor to increase energy expenditure, promote fat breakdown, and modulate appetite-related peripheral signaling; developed for subcutaneous administration with an approximate PK half-life supporting weekly or monthly dosing.
Investigational peripheral CB1-inhibiting monoclonal antibody (investigational obesity candidate)
A peripherally restricted monoclonal antibody that negatively modulates the CB1 receptor to increase energy expenditure, promote fat breakdown, and modulate appetite-related peripheral signaling; developed for subcutaneous administration with an approximate PK half-life supporting weekly or monthly dosing.
Services
Sponsorship and operational execution of Phase 2 clinical studies including protocol design, randomization, blinding strategies, endpoint selection, and safety follow-up.
Collaborative formulation development projects to optimize subcutaneous formulations for investigational biologics.
Sponsorship and operational execution of Phase 2 clinical studies including protocol design, randomization, blinding strategies, endpoint selection, and safety follow-up.
Collaborative formulation development projects to optimize subcutaneous formulations for investigational biologics.
Expertise Areas
- Clinical trial management
- Biologics (monoclonal antibody) development
- Translational pharmacology
- Biomarker discovery and strategy
Key Technologies
- Monoclonal antibody therapeutics
- GPCR allosteric modulation (negative allosteric modulator/inverse agonist)
- Peripheral CB1 inhibition mechanism
- Diet-induced obesity animal models